Antibiotic prophylaxis at dental implant placement: Which is the best protocol? A systematic review and network meta-analysis.

adverse events antibiotic prophylaxis early failures early implant failures implant placement implant survival network meta-analysis penicillins side effects systematic review

Journal

Journal of clinical periodontology
ISSN: 1600-051X
Titre abrégé: J Clin Periodontol
Pays: United States
ID NLM: 0425123

Informations de publication

Date de publication:
03 2019
Historique:
received: 20 09 2018
revised: 28 01 2019
accepted: 02 02 2019
pubmed: 8 2 2019
medline: 18 12 2019
entrez: 8 2 2019
Statut: ppublish

Résumé

This systematic review of randomized controlled trials (RCTs) aims to answer to the following question: "In patients undergoing dental implant placement, which is the best antibiotic prophylaxis protocol to prevent early failures?" The MEDLINE, SCOPUS, CENTRAL and Web of Knowledge electronic databases were searched in duplicate for RCTs up to July 2017. Additional relevant literature was identified through (i) handsearching on both relevant journals and reference lists, and (ii) searching in databases for grey literature. A network meta-analysis (NMA) was conducted, and the probability that each protocol is the "Best" was estimated. Nine RCTs were included, with a total of 1,693 participants. Due to the few events reported, it was not possible to conduct a NMA for adverse events, therefore it was conducted only for implant failures (IF). The protocol with the highest probability (32.5%) of being the "Best" one to prevent IF was the single dose of 3 g of amoxicillin administered 1 hr pre-operatively. Even if the single pre-operative dose of 2 g of amoxicillin is the most used, it achieved only a probability of 0.2% to be the "Best" one. Basing on the available RCTs, the use of antibiotic prophylaxis is protective against early implant failures. Whenever an antibiotic prophylaxis is needed, there is still insufficient evidence to confidently recommend a specific dosage. The use of post-operative courses does not seem however to be justified by the available literature. Prospero registration number: CRD42015029708.

Identifiants

pubmed: 30729548
doi: 10.1111/jcpe.13080
doi:

Substances chimiques

Anti-Bacterial Agents 0
Dental Implants 0
Amoxicillin 804826J2HU

Types de publication

Journal Article Meta-Analysis Review Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

382-395

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Auteurs

Mario Romandini (M)

Department of Medical, Oral and Biotechnological Sciences, University of Chieti-Pescara, Chieti, Italy.
Institute of Dentistry and Maxillofacial, Surgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy.
PhD Candidate and Postgraduate Student in the EFP Program in Periodontology at Complutense University, Madrid, Spain.

Ilaria De Tullio (I)

Department of Medical, Oral and Biotechnological Sciences, University of Chieti-Pescara, Chieti, Italy.

Francesca Congedi (F)

Department of Medical, Oral and Biotechnological Sciences, University of Chieti-Pescara, Chieti, Italy.

Zamira Kalemaj (Z)

Private Practice, Milan, Italy.

Mattia D'Ambrosio (M)

Department of Medical, Oral and Biotechnological Sciences, University of Chieti-Pescara, Chieti, Italy.
Unit of Oral and Maxillofacial Surgery, Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.

Andreina Laforí (A)

Private Practice, Rome, Italy.

Ciro Quaranta (C)

Department of Medical, Oral and Biotechnological Sciences, University of Chieti-Pescara, Chieti, Italy.

Jacopo Buti (J)

Unit of Periodontology, Eastman Dental Institute - University College London, London, UK.

Giorgio Perfetti (G)

Department of Medical, Oral and Biotechnological Sciences, University of Chieti-Pescara, Chieti, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH